From 4 October, the All Wales Therapeutics and Toxicology Centre (AWTTC) will be working with colleagues in the Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) as a partner in the new Innovative Licensing and Access Pathway (ILAP).
The aim is to provide a single integrated platform for sustained collaborative working which will reduce the time to market for new innovative medicines and ensure that patients have timely access to a wide range of medicines including advanced therapy medicinal products (ATMPs), medicines for rare diseases and repurposed medicines.
Read more about the Innovative Licensing and Access Pathway.